Gut microbiome changes improve outcomes in kidney cancer
In a Phase I trial, patients with metastatic kidney cancer who took a live biotherapeutic product alongside immunotherapy and enzymatic tyrosine kinase inhibitors experienced improved health outcomes. City of Hope, US, researchers are now in discussions with the global SWOG Cancer Research Network to design a… Read More
